Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jae-Cheol Jo, Youngwoo Jeon, DaJung Kim, Deok-Hwan Yang, Won Sik Lee, Yoon Seok Choi, Jun Ho Yi, Dok Hyun Yoon, Jee Hyun Kong, Jung-Yoon Choe, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Hana Ju, Soonbum Kwon & Seok-Goo Cho. (2023) A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea. Expert Opinion on Biological Therapy 23:8, pages 737-747.
Read now
Read now
Ali McBride, Karen MacDonald, Adolfo Fuentes-Alburo & Ivo Abraham. (2021) Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of Medical Economics 24:1, pages 743-756.
Read now
Read now
Articles from other publishers (2)
Allini Mafra, Mathieu Laversanne, Mary Gospodarowicz, Paulo Klinger, Neimar De Paula Silva, Marion Piñeros, Eva Steliarova‐Foucher, Freddie Bray & Ariana Znaor. (2022)
Global patterns of
non‐Hodgkin
lymphoma in 2020
. International Journal of Cancer 151:9, pages 1474-1481.
Crossref
Crossref
Dasom Choi, Soohyun Lee, Seungmin Kim & Sangwook Yoon. (2022) A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10. Clinical Drug Investigation 42:4, pages 285-300.
Crossref
Crossref